82956-11-4 | Nafamostat mesylate

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$18.00	$12.00
10mg	95%	in stock	$26.00	$18.00
50mg	95%	in stock	$35.00	$24.00
100mg	95%	in stock	$63.00	$45.00
250mg	95%	in stock	$70.00	$49.00
1g	95%	in stock	$208.00	$146.00
5g	95%	in stock	$707.00	$495.00

Description

• Catalog Number: AB76970
• Chemical Name: Nafamostat mesylate
• CAS Number: 82956-11-4
• Molecular Formula: C21H25N5O8S2
• Molecular Weight: 539.5819
• MDL Number: MFCD00941430
• SMILES: CS(=O)(=O)O.CS(=O)(=O)O.NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N

Computed Properties

• Complexity: 645
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 6
• Rotatable Bond Count: 5

Literature

• Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.

  Medicine 20151201

• Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition.

  Scientific reports 20140101

• Nafamostat mesilate, a noncalcium compound, as an anticoagulant, induces calcium-dependent haemolysis when infused with packed erythrocytes.

  Transfusion medicine (Oxford, England) 20120601

• [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20120301

• Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

  The American journal of pathology 20120101

• The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.

  Renal failure 20120101

• Protease activity increases in plasma, peritoneal fluid, and vital organs after hemorrhagic shock in rats.

  PloS one 20120101

• Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis.

  Arthritis research & therapy 20120101

• Breakdown of mucin as barrier to digestive enzymes in the ischemic rat small intestine.

  PloS one 20120101

• Nafamostat mesilate, a potent tryptase inhibitor, modulates periodontitis in rats.

  Clinical oral investigations 20111201

• Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?

  Pancreas 20111101

• The pharmacological profile of brain liver intestine Na+ channel: inhibition by diarylamidines and activation by fenamates.

  Molecular pharmacology 20111101

• Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.

  Journal of hepato-biliary-pancreatic sciences 20110901

• Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110801

• Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.

  Cancer letters 20110701

• Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.

  Journal of Korean medical science 20110701

• Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.

  The International journal of artificial organs 20110701

• RNA interference inhibits high mobility group box 1 by lipopolysaccharide-activated murine macrophage RAW 264.7 secretion.

  The Journal of surgical research 20110615

• Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer.

  Pancreas 20110501

• Nafamostat mesilate attenuates Postreperfusion Syndrome during liver transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20110501

• Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis.

  International immunopharmacology 20110401

• Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.

  Pancreas 20110301

• [Synthetic protease inhibitors for the treatment of DIC].

  Rinsho byori. The Japanese journal of clinical pathology 20110201

• Protease inhibitor nafamostat mesilate attenuates complement activation and improves function of xenografts in a discordant lung perfusion model.

  Xenotransplantation 20110101

• Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells.

  Journal of immunology (Baltimore, Md. : 1950) 20101215

• The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice.

  Life sciences 20101120

• Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.

  Oncology reports 20101001

• The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study.

  Pancreas 20100801

• Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium.

  Journal of anesthesia 20100801

• Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate.

  Acta dermato-venereologica 20100701

• Inhibition of intraluminal pancreatic enzymes with nafamostat mesilate improves clinical outcomes after hemorrhagic shock in swine.

  The Journal of trauma 20100501

• Nafamostat mesilate is not appropriate as an anticoagulant during continuous renal replacement therapy in dogs.

  The Journal of veterinary medical science 20100301

• Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat.

  Acta neurochirurgica. Supplement 20100101

• [Treatment of disseminated intravascular coagulation].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100101

• Anticoagulation in acute blood purification for acute renal failure in critical care.

  Contributions to nephrology 20100101

• The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations.

  Molecular brain 20100101

• Biological effect of anaphylatoxin C5a on the generation of anti-inflammatory substances in leukocyte adsorption.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20091201

• Effects of nafamostat mesilate on coagulopathy with chronic aortic dissection.

  The Annals of thoracic surgery 20091001

• The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis.

  The American journal of pathology 20090801

• Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.

  Anticancer research 20090801

• Brugada-like electrocardiographic pattern due to hyperkalemia.

  Clinical cardiology 20090701

• Effect of low-molecular weight trypsin inhibitor, nafamostat mesilate, on trypsin activity using the pancreatic acinar cells.

  Pancreas 20090701

• Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.

  Gastrointestinal endoscopy 20090401

• Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report.

  Journal of pediatric hematology/oncology 20090301

• Involvement of Tryptase and Proteinase-Activated Receptor-2 in Spontaneous Itch-Associated Response in Mice With Atopy-like Dermatitis.

  Journal of pharmacological sciences 20090301

• A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Mast cells reduce survival of myenteric neurons in culture.

  Neuropharmacology 20090201

• The new strategy of liver transplantation from marginal donors using serine protease inhibitor.

  Transplantation proceedings 20090101

• Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis.

  Journal of gastroenterology 20090101

• Successful treatment of Kasabach-Merritt syndrome with vincristine and diagnosis of the hemangioma using three-dimensional imaging.

  Pediatric hematology and oncology 20090101

• Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.

  Renal failure 20090101

• Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model.

  Journal of anesthesia 20090101

• The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.

  Diabetes & vascular disease research 20090101

• Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome.

  Journal of neuroimmunology 20081215

• Structure of human prostasin, a target for the regulation of hypertension.

  The Journal of biological chemistry 20081212

• An in vivo approach for globally estimating the drug flow between blood and tissue for nafamostat mesilate: the main hydrolysis site determination in human.

  Biological & pharmaceutical bulletin 20081101

• Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.

  Journal of pharmacological sciences 20081101

• Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20081001

• Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition.

  Journal of cardiovascular pharmacology 20080801

• A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study.

  Analytical and bioanalytical chemistry 20080601

• Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis.

  Biochemical and biophysical research communications 20080530

• Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.

  Pancreas 20080401

• Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion.

  American journal of physiology. Heart and circulatory physiology 20080301

• Dramatic improvement of subcutaneous insulin resistance with nafamostat ointment treatment.

  Diabetes care 20080301

• Characteristics of gabexate mesilate-induced cell injury in porcine aorta endothelial cells.

  Journal of pharmacological sciences 20080301

• Effects of direct haemoperfusion through fibres immobilizing polymyxin B and nafamostat mesilate on endotoxaemia in conscious Guinea-pigs.

  Clinical and experimental pharmacology & physiology 20080101

• Pancreaticoduodenectomy for bile duct carcinoma of a patient undergoing hemodialysis.

  Hepato-gastroenterology 20080101

• A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis.

  Modern rheumatology 20080101

• Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.

  Auris, nasus, larynx 20071201

• Nafamostat mesilate reversibly blocks acid-sensing ion channel currents.

  Biochemical and biophysical research communications 20071109

• Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

  Intensive care medicine 20070901

• Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis.

  Journal of gastroenterology 20070801

• Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage.

  Interactive cardiovascular and thoracic surgery 20070601

• [Uremic pericarditis].

  Nihon rinsho. Japanese journal of clinical medicine 20070528

• Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.

  Cancer 20070515

• Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7.

  Shock (Augusta, Ga.) 20070401

• Nafamostat is hydrolysed by human liver cytosolic long-chain acyl-CoA hydrolase.

  Xenobiotica; the fate of foreign compounds in biological systems 20070301

• Low-volume continuous hemodiafiltration with nafamostat mesilate increases trypsin clearance without decreasing plasma trypsin concentration in severe acute pancreatitis.

  ASAIO journal (American Society for Artificial Internal Organs : 1992) 20070101

• Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.

  Journal of anesthesia 20070101

• Aprotinin and nafamostat mesilate in liver surgery: effect on blood loss.

  Digestive surgery 20070101

• Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.

  Blood purification 20070101

• Helicobacter pylori activates gastric epithelial cells to produce interleukin-8 via protease-activated receptor 2.

  Digestion 20070101

• Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells.

  Digestive diseases and sciences 20061101

• Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis.

  Scandinavian journal of gastroenterology 20060801

• Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.

  The Journal of allergy and clinical immunology 20060701

• [Prostasin].

  Nihon rinsho. Japanese journal of clinical medicine 20060701

• Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.

  International journal of pharmaceutics 20060511

• Complement activation is involved in biological responses to leukocyte adsorptive apheresis.

  Digestive diseases and sciences 20060501

• [Postoperative acute pulmonary thromboembolism treated with nafamostat mesilate].

  Masui. The Japanese journal of anesthesiology 20060501

• Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation.

  Xenotransplantation 20060501

• Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.

  The Journal of trauma 20060401

• Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis.

  Drug metabolism and pharmacokinetics 20060401

• Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20060201

• Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice.

  European journal of pharmacology 20060113

• Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060101

• [Quality of life in surgical treatment of pancreatic cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20060101

• The role of a protease inhibitor against hepatectomy.

  Hepato-gastroenterology 20060101

• Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.

  ASAIO journal (American Society for Artificial Internal Organs : 1992) 20060101

• Involvement of neutrophil recruitment and protease-activated receptor 2 activation in the induction of IL-18 in mice.

  Journal of leukocyte biology 20051101

• Effect of intraportal infusion to improve small for size graft injury in living donor adult liver transplantation.

  Transplant international : official journal of the European Society for Organ Transplantation 20050801

• Nafamostat mesilate induces production of interleukin-12 and -18 in human peripheral blood mononuclear cells.

  Journal of pharmacological sciences 20050801

• Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners.

  Journal of pharmacological sciences 20050801

• Small volume resuscitation with hypertonic saline is more effective in ameliorating trauma-hemorrhagic shock-induced lung injury, neutrophil activation and red blood cell dysfunction than pancreatitic protease inhibition.

  The Journal of trauma 20050801

• Open heart surgery in a patient with paroxysmal nocturnal hemoglobinuria.

  The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi 20050601

• Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis.

  Pancreas 20050401

• Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration.

  Artificial organs 20050401

• Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.

  The Annals of thoracic surgery 20050401

• [A patient with Vibrio vulnificus meningoencephalitis].

  Rinsho shinkeigaku = Clinical neurology 20050101

• A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.

  Circulation journal : official journal of the Japanese Circulation Society 20041201

• A serine protease inhibitor, nafamostat mesilate, suppresses aldosterone secretions in vivo.

  Hypertension research : official journal of the Japanese Society of Hypertension 20041201

• Pancreatic proteases and inflammatory mediators in peritoneal fluid during splanchnic arterial occlusion and reperfusion.

  Shock (Augusta, Ga.) 20041101

• [Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].

  Nihon rinsho. Japanese journal of clinical medicine 20041101

• [Continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis].

  Nihon rinsho. Japanese journal of clinical medicine 20041101

• [Role of pancreatic enzymes in gut injury secondary to trauma/hemorrhagic shock in rats].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20041001

• Continuous hemodiafiltration in pediatric critical care patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20041001

• Advanced glycation end products induce secretion of chemokines and apoptosis in human first trimester trophoblasts.

  Human reproduction (Oxford, England) 20040901

• Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis.

  Thrombosis and haemostasis 20040701

• [Blood purification for patients with chronic renal failure accompanied by severe liver disease].

  Nihon rinsho. Japanese journal of clinical medicine 20040601

• [Treatment of uremic patients with high bleeding risk].

  Nihon rinsho. Japanese journal of clinical medicine 20040601

• [Heparin-induced thrombocytopenia in patients on hemodialysis].

  Nihon rinsho. Japanese journal of clinical medicine 20040601

• [Pregnancy and delivery in patients with hemodialysis].

  Nihon rinsho. Japanese journal of clinical medicine 20040601

• Effects of anti-inflammatory cytokine agent (FR167653) and serine protease inhibitor on warm ischemia-reperfusion injury of the liver graft.

  Transplantation 20040527

• Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit.

  Pancreas 20040501

• [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].

  Nihon rinsho. Japanese journal of clinical medicine 20040501

• [How to use anticoagulants in hemodialysis therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20040501

• [Anticoagulation for plasmapheresis].

  Nihon rinsho. Japanese journal of clinical medicine 20040501

• [Anticoagulant].

  Nihon rinsho. Japanese journal of clinical medicine 20040501

• [Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports].

  Journal of cardiology 20040401

• Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.

  The Journal of trauma 20040301

• Transporter-mediated renal handling of nafamostat mesilate.

  Journal of pharmaceutical sciences 20040201

• Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.

  The Annals of thoracic surgery 20040201

• Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20040201

• IL-15 levels in patients with acute hepatic failure.

  Research communications in molecular pathology and pharmacology 20040101

• Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20031001

• Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages.

  International immunopharmacology 20030901

• Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells.

  Cellular signalling 20030801

• Nafamostat mesilate is an extremely potent inhibitor of human tryptase.

  Journal of pharmacological sciences 20030801

• Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.

  Clinical nephrology 20030601

• Successful adult ABO-incompatible liver transplantation: therapeutic strategy for thrombotic microangiopathy is the key to success.

  Transplantation 20030515

• Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury.

  Shock (Augusta, Ga.) 20030501

• Influence of heparin dosage on hemostasis under combined use of Nafamostat mesilate during deep hypothermic circulatory arrest.

  The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi 20030501

• Changes in blood viscosity with synthetic protease inhibitors.

  Journal of pharmacological sciences 20030401

• A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.

  British journal of pharmacology 20030301

• Inhibition of prostasin secretion by serine protease inhibitors in the kidney.

  Journal of the American Society of Nephrology : JASN 20030101

• In vitro relationship between the blood nafamostat concentration and activated coagulation time.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20030101

• Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient.

  Internal medicine (Tokyo, Japan) 20021001

• Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation.

  The Journal of thoracic and cardiovascular surgery 20020901

• [A case with severe acute pancreatitis treated by regional arterial infusion of nafamostat mesilate and imipenem via both celiac artery and superior mesenteric artery].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20020901

• Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits.

  Proteomics 20020801

• [Management of intraoperative anticoagulantless CHD with EVAL-dialyzer in four patients on maintenance hemodialysis].

  Masui. The Japanese journal of anesthesiology 20020301

• Case of a bleeding pseudoaneurysm of the middle colic artery complicating acute pancreatitis.

  Hepato-gastroenterology 20020101

• Inhibition of natural killer cytotoxicity in vitro by clinical grade serine protease inhibitors.

  Haematologia 20020101

• Induction of IkappaB-kinase by cholecystokinin is mediated by trypsinogen activation in rat pancreatic lobules.

  Digestion 20020101

• [A case of pancreatic ascites due to rupture of pancreatic pseudocyst successfully treated with continuous arterial infusion of nafamostat mesilate].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011101

• Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)?

  Thrombosis and haemostasis 20011001

• [Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010901

• Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.

  Anti-cancer drugs 20010901

• Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis.

  Surgery 20010801

• [Anti-bleeding effect of nafamostat mesilate for the surgery of thoracic ascending aorta].

  Kyobu geka. The Japanese journal of thoracic surgery 20010801

• Successful treatment of severe acute pancreatitis by the combination therapy of continuous arterial infusion of a protease inhibitor and continuous hemofiltration.

  Journal of gastroenterology and hepatology 20010801

• Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB.

  Stroke 20010701

• The efficacy of nafamostat mesilate on the performance of a hybrid-artificial liver using a polyurethane foam/porcine hepatocyte spheroid culture system in human plasma.

  The International journal of artificial organs 20010101

• Attenuation of hepatic ischemia and reperfusion injury by serine protease inhibitor, FUT-175, in dogs.

  Transplantation proceedings 20010101

• Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20010101

• Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20010101

• Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20010101

• A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate.

  British journal of anaesthesia 19990901

• Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol.

  British journal of anaesthesia 19981201

• Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.

  British journal of pharmacology 19940101

• Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.

  Internal medicine (Tokyo, Japan) 19921101

• [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease].

  Rinsho shinkeigaku = Clinical neurology 19910101